Cantor Fitzgerald Reaffirms “Overweight” Rating for Agios Pharmaceuticals (NASDAQ:AGIO)

Cantor Fitzgerald reissued their overweight rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report published on Friday, Benzinga reports.

Several other research firms have also recently issued reports on AGIO. The Goldman Sachs Group upped their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a research note on Tuesday, June 4th. Royal Bank of Canada restated an outperform rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday. StockNews.com downgraded shares of Agios Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, August 5th. Finally, JPMorgan Chase & Co. reissued a neutral rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of Hold and an average target price of $51.33.

Agios Pharmaceuticals Trading Down 1.8 %

AGIO stock opened at $46.55 on Friday. The stock’s 50 day simple moving average is $45.71 and its 200 day simple moving average is $39.24. Agios Pharmaceuticals has a 12-month low of $19.80 and a 12-month high of $50.35. The stock has a market capitalization of $2.64 billion, a PE ratio of -7.37 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The business had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $9.34 million. During the same quarter in the prior year, the firm earned ($1.51) EPS. The firm’s revenue for the quarter was up 28.4% compared to the same quarter last year. On average, research analysts predict that Agios Pharmaceuticals will post -4.85 earnings per share for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.93% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caxton Associates LP lifted its holdings in Agios Pharmaceuticals by 0.7% during the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after purchasing an additional 264 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Agios Pharmaceuticals by 0.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,148,000 after buying an additional 314 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in Agios Pharmaceuticals by 1.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock worth $911,000 after buying an additional 540 shares during the period. Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals in the 2nd quarter worth $37,000. Finally, Quest Partners LLC bought a new stake in Agios Pharmaceuticals during the second quarter valued at about $40,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.